Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Soliris
Soliris
EHA 2023 – Astrazeneca keeps up its complement defense
EHA 2023 – Astrazeneca keeps up its complement defense
EP Vantage
EHA
AstraZeneca
Alexion
Soliris
Ultomiris
Novartis
iptacopan
PNH
Flag link:
Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3
Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3
Fierce Biotech
Roche
PNH
AstraZeneca
crovalimab
Soliris
Flag link:
AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in
Fierce Biotech
AstraZeneca
Alexion
PNH
Ultomiris
Soliris
Roche
Apellis
Novartis
Flag link:
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
ASH: Roche records phase 3 rare disease win ahead of Soliris showdown
Fierce Biotech
ASH 2022
Roche
PNH
crovalimab
AstraZeneca
Soliris
Flag link:
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Fierce Biotech
Novartis
iptacopan
clinical trials
Soliris
AstraZeneca
Ultomiris
Flag link:
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Could This Biosimilar Drug Candidate Be a Winner for Amgen?
Motley Fool
Amgen
Soliris
biosimilars
ABP 959
Flag link:
Roche and AstraZeneca settle years long patent battle over Ultomiris — report
Roche and AstraZeneca settle years long patent battle over Ultomiris — report
Endpoints
Roche
Chugai
AstraZeneca
Alexion
patents
Ultomiris
Soliris
Flag link:
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Endpoints
UCB Pharma
clinical trials
myasthenia gravis
AstraZeneca
Soliris
zilucoplan
Flag link:
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
Fierce Pharma
AstraZeneca
Soliris
Alexion
drug pricing
myasthenia gravis
Flag link:
Genentech posts long-term data on near-approval Soliris rival
Genentech posts long-term data on near-approval Soliris rival
Fierce Biotech
Genentech
satralizumab
Soliris
Alexion
NMOSD
Flag link:
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Fierce Pharma
Alexion
COVID-19
clinical trials
Soliris
Flag link:
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels
Reuters
Apellis Pharmaceuticals
Alexion Pharmaceuticals
PNH
pegcetacoplan
Soliris
Flag link:
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
oncology
Rare Diseases
AstraZeneca
GSK
Alexion
Takeda
Soliris
Flag link:
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Xconomy
Alexion Pharmaceuticals
Achillion
M&A
PNH
danicopan
Soliris
Flag link:
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
Fierce Biotech
UCB Pharma
Ra Pharmaceuticals
M&A
zilucoplan
Alexion
Soliris
Flag link:
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Achillion
FDA
paroxysmal nocturnal hemoglobinuria
Soliris
PNH
Flag link:
Alexion shares slide on Amgen patent challenge to top-seller
Alexion shares slide on Amgen patent challenge to top-seller
Biopharma Dive
Amgen
Alexion
inter partes review
patents
Soliris
Flag link:
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Fierce Pharma
Alexion
Soliris
Ultomiris
PNH
Flag link:
Alexion’s Soliris follow-up Ultomiris snares EU approval
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Flag link:
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Alexion
Soliris
FDA
autoimmune disease
NMOSD
Flag link:
Pages
1
2
3
4
5
next ›
last »